A phase I-B study of an anti-IL-15 antibody in vitiligo showed 42% of patients achieved ≥50% facial improvement at 24 weeks with quarterly dosing, favorable safety, and strong patient-reported outcomes. The therapy is positioned for further development in vitiligo and related autoimmune diseases.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.